Company news

Vaxcyte, Inc. news in 2025

Vaxcyte, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

December 7, 2025

Medicxi Announces €500 Million Fund V

November 14, 2025

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

November 3, 2025

Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

September 29, 2025

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

September 2, 2025

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

August 5, 2025

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

April 30, 2025

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

March 30, 2025

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

March 29, 2025

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 24, 2025

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

February 11, 2025

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

February 4, 2025

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

January 29, 2025

Calls in 2025

Decks in 2025